RBOT
Vicarious Surgical Inc.·Healthcare
0.70
6.667%(−0.05)
Market ClosedLast Updated: — ET
52W L: $0.2752W H: $13.75
RBOT NEWS
globenewswire.com
Mar 30
Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone.
globenewswire.com
Mar 25
Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the “OTCQB”).
defenseworld.net
Mar 19
Head-To-Head Survey: Waters (NYSE:WAT) vs. Vicarious Surgical (NYSE:RBOT)
Waters (NYSE: WAT - Get Free Report) and Vicarious Surgical (NYSE: RBOT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Insider and Institutional Ownership 94.0% of Waters shares are
businesswire.com
Mar 16
Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (OTCID: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery, today announced a series of strategic actions intended to strengthen the Company's financial position, enhance trading liquidity, and support a potential relisting of its common stock on a national exchange. Over the past several months, Vicarious Surgical has implemented significant operational and cost discipline initiatives des.
businesswire.com
Mar 9
Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCID: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results Total operating expenses were $9.3 million in the fourth quarter of 2025, and $15.0 million in the fourth quarter of 2024, a decrease of 38%. Researc.
businesswire.com
Mar 4
Vicarious Surgical Receives Delisting Notice From NYSE
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”). Trading on the Company's Common Stock on the NYS.
